160 related articles for article (PubMed ID: 24429222)
1. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
Leucht S; Zhao J
J Psychopharmacol; 2014 Apr; 28(4):387-94. PubMed ID: 24429222
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis.
Potkin SG; Phiri P; Szegedi A; Zhao J; Alphs L; Cazorla P
Schizophr Res; 2013 Nov; 150(2-3):442-9. PubMed ID: 24075603
[TBL] [Abstract][Full Text] [Related]
3. Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program.
Szegedi A; Zhao J; McIntyre RS
J Affect Disord; 2013 Sep; 150(3):745-52. PubMed ID: 23473546
[TBL] [Abstract][Full Text] [Related]
4. Management of depressive symptoms in schizophrenia.
Castle DJ; Slott Jensen JK
Clin Schizophr Relat Psychoses; 2015 Apr; 9(1):13-20. PubMed ID: 25367164
[TBL] [Abstract][Full Text] [Related]
5. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
Szegedi A; Verweij P; van Duijnhoven W; Mackle M; Cazorla P; Fennema H
J Clin Psychiatry; 2012 Dec; 73(12):1533-40. PubMed ID: 23290326
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
7. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
Buchanan RW; Panagides J; Zhao J; Phiri P; den Hollander W; Ha X; Kouassi A; Alphs L; Schooler N; Szegedi A; Cazorla P
J Clin Psychopharmacol; 2012 Feb; 32(1):36-45. PubMed ID: 22198451
[TBL] [Abstract][Full Text] [Related]
8. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.
Ascher-Svanum H; Zhao F; Detke HC; Nyhuis AW; Lawson AH; Stauffer VL; Montgomery W; Witte MM; McDonnell DP
BMC Psychiatry; 2011 Sep; 11():152. PubMed ID: 21943257
[TBL] [Abstract][Full Text] [Related]
9. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM
Neuropsychopharmacology; 2010 Jan; 35(2):581-90. PubMed ID: 19890258
[TBL] [Abstract][Full Text] [Related]
10. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.
Hatta K; Otachi T; Sudo Y; Hayakawa T; Ashizawa Y; Takebayashi H; Hayashi N; Hamakawa H; Ito S; Nakase R; Usui C; Nakamura H; Hirata T; Sawa Y;
Schizophr Res; 2011 May; 128(1-3):127-35. PubMed ID: 21420283
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
12. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
[TBL] [Abstract][Full Text] [Related]
13. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.
Landbloom R; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
CNS Spectr; 2017 Aug; 22(4):333-341. PubMed ID: 27821210
[TBL] [Abstract][Full Text] [Related]
14. Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.
Stentebjerg-Olesen M; Ganocy SJ; Findling RL; Chang K; DelBello MP; Kane JM; Tohen M; Jeppesen P; Correll CU
Eur Child Adolesc Psychiatry; 2015 Dec; 24(12):1485-96. PubMed ID: 26032132
[TBL] [Abstract][Full Text] [Related]
15. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
[TBL] [Abstract][Full Text] [Related]
16. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
Sauriol L; Laporta M; Edwardes MD; Deslandes M; Ricard N; Suissa S
Clin Ther; 2001 Jun; 23(6):942-56. PubMed ID: 11440294
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of early improvement in bipolar depression trials: a post-hoc pooled analysis of two 8-week aripiprazole studies.
Kemp DE; Calabrese JR; Eudicone JM; Ganocy S; Tran QV; McQuade RD; Marcus RN; Vester-Blokland E; Owen R; Carlson BX
Psychopharmacol Bull; 2010; 43(2):5-27. PubMed ID: 21052040
[TBL] [Abstract][Full Text] [Related]
19. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.
McIntyre RS; Tohen M; Berk M; Zhao J; Weiller E
J Affect Disord; 2013 Sep; 150(2):378-83. PubMed ID: 23712026
[TBL] [Abstract][Full Text] [Related]
20. Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.
Schoemaker J; Naber D; Vrijland P; Panagides J; Emsley R
Pharmacopsychiatry; 2010 Jun; 43(4):138-46. PubMed ID: 20205074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
